Literature DB >> 29708629

Defining the molecular mechanisms of HIV-1 Tat secretion: PtdIns(4,5)P2 at the epicenter.

Anthony R Mele1,2, Jamie Marino1,2, Kenneth Chen3, Vanessa Pirrone1,2, Chris Janetopoulos3, Brian Wigdahl1,2,4, Zachary Klase3, Michael R Nonnemacher1,2,4.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) transactivator of transcription (Tat) protein functions both intracellularly and extracellularly. Intracellularly, the main function is to enhance transcription of the viral promoter. However, this process only requires a small amount of intracellular Tat. The majority of Tat is secreted through an unconventional mechanism by binding to phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2 ), a phospholipid in the inner leaflet of the plasma membrane that is required for secretion. This interaction is mediated by the basic domain of Tat (residues 48-57) and a conserved tryptophan (residue 11). After binding to PtdIns(4,5)P2 , Tat secretion diverges into multiple pathways, which we categorized as oligomerization-mediated pore formation, spontaneous translocation and incorporation into exosomes. Extracellular Tat has been shown to be neurotoxic and toxic to other cells of the central nervous system (CNS) and periphery, able to recruit immune cells to the CNS and cerebrospinal fluid, and alter the gene expression and morphology of uninfected cells. The effects of extracellular Tat have been examined in HIV-1-associated neurocognitive disorders (HAND); however, only a small number of studies have focused on the mechanisms underlying Tat secretion. In this review, the molecular mechanisms of Tat secretion will be examined in a variety of biologically relevant cell types.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  HIV-1; PtdIns(4,5)P2; T-cell; Tat; astrocyte; exosome; monocyte-macrophage; secretion

Year:  2018        PMID: 29708629      PMCID: PMC6207469          DOI: 10.1111/tra.12578

Source DB:  PubMed          Journal:  Traffic        ISSN: 1398-9219            Impact factor:   6.215


  112 in total

1.  Human immunodeficiency virus type 1 tat protein activates transcription factor NF-kappaB through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR.

Authors:  F Demarchi; M I Gutierrez; M Giacca
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Antiretroviral therapy does not block the secretion of the human immunodeficiency virus tat protein.

Authors:  Sonia Mediouni; Albert Darque; Gilbert Baillat; Isabelle Ravaux; Catherine Dhiver; Herve Tissot-Dupont; Malika Mokhtari; Herve Moreau; Catherine Tamalet; Corinne Brunet; Pascale Paul; Francoise Dignat-George; Andreas Stein; Philippe Brouqui; Stephen A Spector; Grant R Campbell; Erwann P Loret
Journal:  Infect Disord Drug Targets       Date:  2012-02

3.  Exosomal Tat protein activates latent HIV-1 in primary, resting CD4+ T lymphocytes.

Authors:  Xiaoli Tang; Huafei Lu; Mark Dooner; Stacey Chapman; Peter J Quesenberry; Bharat Ramratnam
Journal:  JCI Insight       Date:  2018-04-05

Review 4.  PTEN: The down side of PI 3-kinase signalling.

Authors:  Nick R Leslie; C Peter Downes
Journal:  Cell Signal       Date:  2002-04       Impact factor: 4.315

Review 5.  PIP5K-driven PtdIns(4,5)P2 synthesis: regulation and cellular functions.

Authors:  Iman van den Bout; Nullin Divecha
Journal:  J Cell Sci       Date:  2009-11-01       Impact factor: 5.285

6.  Acetylation of Tat defines a cyclinT1-independent step in HIV transactivation.

Authors:  Katrin Kaehlcke; Alexander Dorr; Claudia Hetzer-Egger; Veronique Kiermer; Peter Henklein; Martina Schnoelzer; Erwann Loret; Philip A Cole; Eric Verdin; Melanie Ott
Journal:  Mol Cell       Date:  2003-07       Impact factor: 17.970

7.  Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation.

Authors:  B Ensoli; L Buonaguro; G Barillari; V Fiorelli; R Gendelman; R A Morgan; P Wingfield; R C Gallo
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

8.  Exogenous tat protein activates central nervous system-derived endothelial cells.

Authors:  F M Hofman; M M Dohadwala; A D Wright; D R Hinton; S M Walker
Journal:  J Neuroimmunol       Date:  1994-10       Impact factor: 3.478

9.  Clade C HIV-1 isolates circulating in Southern Africa exhibit a greater frequency of dicysteine motif-containing Tat variants than those in Southeast Asia and cause increased neurovirulence.

Authors:  Vasudev R Rao; Ujjwal Neogi; Joshua S Talboom; Ligia Padilla; Mustafizur Rahman; Cari Fritz-French; Sandra Gonzalez-Ramirez; Anjali Verma; Charles Wood; Ruth M Ruprecht; Udaykumar Ranga; Tasnim Azim; John Joska; Eliseo Eugenin; Anita Shet; Heather Bimonte-Nelson; William R Tyor; Vinayaka R Prasad
Journal:  Retrovirology       Date:  2013-06-08       Impact factor: 4.602

10.  Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers.

Authors:  Johan Skog; Tom Würdinger; Sjoerd van Rijn; Dimphna H Meijer; Laura Gainche; Miguel Sena-Esteves; William T Curry; Bob S Carter; Anna M Krichevsky; Xandra O Breakefield
Journal:  Nat Cell Biol       Date:  2008-11-16       Impact factor: 28.824

View more
  10 in total

Review 1.  Genetic variation and function of the HIV-1 Tat protein.

Authors:  Cassandra Spector; Anthony R Mele; Brian Wigdahl; Michael R Nonnemacher
Journal:  Med Microbiol Immunol       Date:  2019-03-05       Impact factor: 3.402

2.  Investigating the distribution of HIV-1 Tat lengths present in the Drexel Medicine CARES cohort.

Authors:  Robert W Link; Anthony R Mele; Gregory C Antell; Vanessa Pirrone; Wen Zhong; Katherine Kercher; Shendra Passic; Zsofia Szep; Kim Malone; Jeffrey M Jacobson; Will Dampier; Brian Wigdahl; Michael R Nonnemacher
Journal:  Virus Res       Date:  2019-08-19       Impact factor: 3.303

Review 3.  Unconventional Pathways of Protein Secretion: Mammals vs. Plants.

Authors:  Elisa Maricchiolo; Eleonora Panfili; Andrea Pompa; Francesca De Marchis; Michele Bellucci; Maria Teresa Pallotta
Journal:  Front Cell Dev Biol       Date:  2022-04-28

Review 4.  The Role of Inflammation in Anal Cancer.

Authors:  Amir Selimagic; Ada Dozic; Azra Husic-Selimovic; Nijaz Tucakovic; Amir Cehajic; Anela Subo; Azra Spahic; Nedim Vanis
Journal:  Diseases       Date:  2022-05-06

Review 5.  The role of exosomal transport of viral agents in persistent HIV pathogenesis.

Authors:  Benjamin J Patters; Santosh Kumar
Journal:  Retrovirology       Date:  2018-12-22       Impact factor: 4.602

Review 6.  Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease.

Authors:  Aurelio Cafaro; Antonella Tripiciano; Orietta Picconi; Cecilia Sgadari; Sonia Moretti; Stefano Buttò; Paolo Monini; Barbara Ensoli
Journal:  Vaccines (Basel)       Date:  2019-08-26

Review 7.  Tat-Based Therapies as an Adjuvant for an HIV-1 Functional Cure.

Authors:  Hongping Jin; Dongsheng Li; Min-Hsuan Lin; Li Li; David Harrich
Journal:  Viruses       Date:  2020-04-08       Impact factor: 5.048

8.  Morphine exposure exacerbates HIV-1 Tat driven changes to neuroinflammatory factors in cultured astrocytes.

Authors:  Kenneth Chen; Thienlong Phan; Angel Lin; Luca Sardo; Anthony R Mele; Michael R Nonnemacher; Zachary Klase
Journal:  PLoS One       Date:  2020-03-25       Impact factor: 3.240

9.  HIV-1 Tat Length: Comparative and Functional Considerations.

Authors:  Anthony R Mele; Jamie Marino; Will Dampier; Brian Wigdahl; Michael R Nonnemacher
Journal:  Front Microbiol       Date:  2020-03-24       Impact factor: 5.640

Review 10.  Sirtuins Modulation: A Promising Strategy for HIV-Associated Neurocognitive Impairments.

Authors:  Izchel Figarola-Centurión; Martha Escoto-Delgadillo; Gracia Viviana González-Enríquez; Juan Ernesto Gutiérrez-Sevilla; Eduardo Vázquez-Valls; Blanca Miriam Torres-Mendoza
Journal:  Int J Mol Sci       Date:  2022-01-07       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.